Anti-cancer Therapy Research Fields

Research Fields	Goals	Details
Antibody Screening	Research on developing innovative antibody drugs	To address unmet clinical needs, we are deeply analyzing the pathological mechanisms of target proteins and discovering therapeutic antibodies with potential for treatment. To this end, we systematically analyze the mechanism of action (MOA) and clinical trial data of various drugs to establish the optimal development strategy and design target-centered personalized research.
Immuno-oncology	Development and research of immune checkpoint inhibitors	Our research focuses on developing a novel immune checkpoint inhibitor that specifically targets a particular immune cell subtype to stimulate immune response. Recognizing the diverse roles of various immune checkpoint targets in the tumor microenvironment, we are pursuing multiple drug development strategies tailored to target specific immune cell subtypes for each target.
Immunocytokine	Development of antibody-cytokine fusion proteins	We aim to enhance anti-tumor efficacy by converting cold tumors into hot tumors through the development of immunocytokines, which combine cytokines with antibodies targeting specific antigens. These immunocytokines are designed to directly kill cancer cells and indirectly activate immune cells in the tumor microenvironment (TME).
CAR-X Immunotherapy	Development of allogeneic CAR-X and NK cell immunotherapies	To overcome CAR T cell therapy, we are investigating allogeneic cell therapies using an off-the-shelf approach, where a universal product is created from a single donor and can be administered to multiple patients. In particular, We focus on developing therapies based on iPSC-derived and cord blood-derived NK and T cells, employing innovative gene delivery technologies and efficient large-scale manufacturing strategies.
Abscopal	Study on enhancing the abscopal effect and elucidating its mechanism using phototherapy	We aims to investigate the systemic therapeutic efficacy, including the abscopal effect, of photothermal or photodynamic therapy using tumor-targeted photosensitizers. We will explore the underlying immune mechanisms of the abscopal effect and investigate the synergistic effects of combining immunostimulatory cytokines and immune checkpoint inhibitors to enhance the abscopal effect in treatment-resistant tumors.
Antibody – Omomyc, siRNA conjugate	Development of antibody-Omomyc, asymmetric siRNA therapeutics	Our goal is to improve the delivery of Omomyc and asymmetric siRNA to tumors by conjugating them with antibodies. This approach is expected to increase the specificity of drug delivery, reducing off-target effects, and inducing apoptosis of cancer cells by targeting MYC protein and other cancer-related genes within the tumor microenvironment.